Comparison Azathioprine to Mesalazine for the Prevention of Postoperative Recurrence in the Crohn Disease

A Multicentre Randomized Open Study Comparing Azathioprine to Mesalazine for the Prevention of Postoperative Recurrence in the Crohn Disease

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00976690

Acronym

IMURELPOST

Enrollment

Registered

2009-09-14

Start date

2002-10-31

Completion date

2010-12-31

Last updated

2011-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn Disease

Keywords

Crohn's Disease, Ileocolic resection, Endoscopic recurrence, Ileocolic or colon resection (>50cm)

Brief summary

To show the superiority of Azathioprine comparing Mesalazine in the prevention of postoperative recurrence in Crohn's Disease.

Interventions

DRUGAzathioprine OR Mesalazine

Azathioprine : 2mg/kg/day Mesalazine : 4g/day

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* more than 18 years old * Clinical remission at inclusion time (CDAI\<150) * Having ileocolonic or colon resection 21 days before inclusion * Resection \> 50cm or subtotal colectomy with ileorectal anastomosis

Exclusion criteria

* Intolerance to one of both study treatment * Liver failure (TP\<60%) * Renal Failure (Creatinine \< Lab results)

Design outcomes

Primary

Measure	Time frame
Clinically and endoscopically recurrence at 12 and 24 months	12 and 24 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026